Benitec Biopharma is a clinical-stage biotechnology company focused on the development of genetic medicines. The platform, called DNA-directed RNA interference, combines RNA interference with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. Co. is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a genetic disorder. BB-301 is an adeno-associated viral vectors -based gene therapy designed to silence the expression of the disease-causing gene (to slow, or halt, the biological mechanisms underlying disease progression in OPMD). The BNTC YTD return is shown above.
The YTD Return on the BNTC YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether BNTC YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BNTC YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|